entcancercare ltd
entcancercare ltd Company Information
Company Number
09558725
Next Accounts
Jan 2025
Industry
General medical practice activities
Shareholders
nidhi supriya
mrinal supriya
Group Structure
View All
Contact
Registered Address
2 livesey hill, shenley lodge, milton keynes, buckinghamshire, MK5 7EG
Website
-entcancercare ltd Estimated Valuation
Pomanda estimates the enterprise value of ENTCANCERCARE LTD at £117.8k based on a Turnover of £248.9k and 0.47x industry multiple (adjusted for size and gross margin).
entcancercare ltd Estimated Valuation
Pomanda estimates the enterprise value of ENTCANCERCARE LTD at £200k based on an EBITDA of £54.1k and a 3.7x industry multiple (adjusted for size and gross margin).
entcancercare ltd Estimated Valuation
Pomanda estimates the enterprise value of ENTCANCERCARE LTD at £298.6k based on Net Assets of £107.4k and 2.78x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Entcancercare Ltd Overview
Entcancercare Ltd is a live company located in milton keynes, MK5 7EG with a Companies House number of 09558725. It operates in the general medical practice activities sector, SIC Code 86210. Founded in April 2015, it's largest shareholder is nidhi supriya with a 50% stake. Entcancercare Ltd is a young, micro sized company, Pomanda has estimated its turnover at £248.9k with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Entcancercare Ltd Health Check
Pomanda's financial health check has awarded Entcancercare Ltd a 5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 2 areas for improvement. Company Health Check FAQs
4 Strong
3 Regular
2 Weak
Size
annual sales of £248.9k, make it smaller than the average company (£1.2m)
- Entcancercare Ltd
£1.2m - Industry AVG
Growth
3 year (CAGR) sales growth of 47%, show it is growing at a faster rate (6.1%)
- Entcancercare Ltd
6.1% - Industry AVG
Production
with a gross margin of 42.8%, this company has a comparable cost of product (42.8%)
- Entcancercare Ltd
42.8% - Industry AVG
Profitability
an operating margin of 13.9% make it more profitable than the average company (5.4%)
- Entcancercare Ltd
5.4% - Industry AVG
Employees
with 3 employees, this is below the industry average (15)
3 - Entcancercare Ltd
15 - Industry AVG
Pay Structure
on an average salary of £33.8k, the company has an equivalent pay structure (£33.8k)
- Entcancercare Ltd
£33.8k - Industry AVG
Efficiency
resulting in sales per employee of £83k, this is equally as efficient (£83k)
- Entcancercare Ltd
£83k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Entcancercare Ltd
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Entcancercare Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Entcancercare Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 93 weeks, this is more cash available to meet short term requirements (44 weeks)
93 weeks - Entcancercare Ltd
44 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 29.5%, this is a lower level of debt than the average (51%)
29.5% - Entcancercare Ltd
51% - Industry AVG
ENTCANCERCARE LTD financials
Entcancercare Ltd's latest turnover from April 2023 is estimated at £248.9 thousand and the company has net assets of £107.4 thousand. According to their latest financial statements, Entcancercare Ltd has 3 employees and maintains cash reserves of £29 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||
| Other Income Or Grants | ||||||||
| Cost Of Sales | ||||||||
| Gross Profit | ||||||||
| Admin Expenses | ||||||||
| Operating Profit | ||||||||
| Interest Payable | ||||||||
| Interest Receivable | ||||||||
| Pre-Tax Profit | ||||||||
| Tax | ||||||||
| Profit After Tax | ||||||||
| Dividends Paid | ||||||||
| Retained Profit | ||||||||
| Employee Costs | ||||||||
| Number Of Employees | 3 | 2 | 1 | 1 | 2 | 1 | ||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 77,399 | 73,553 | 38,372 | 44,765 | 35,418 | 1,570 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 39,000 | 20,000 | 10,000 | 0 | 0 | 0 | 0 | 1 |
| Total Fixed Assets | 116,399 | 93,553 | 48,372 | 44,765 | 35,418 | 1,570 | 0 | 1 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 54,467 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 17,589 | 6,200 | 12,120 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 7,000 | 7,000 | 7,000 | 7,000 | 0 | 0 | 0 | 0 |
| Cash | 28,951 | 39,929 | 50,480 | 74,132 | 0 | 0 | 0 | 676 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 35,951 | 46,929 | 57,480 | 81,132 | 54,467 | 17,589 | 6,200 | 12,796 |
| total assets | 152,350 | 140,482 | 105,852 | 125,897 | 89,885 | 19,159 | 6,200 | 12,797 |
| Bank overdraft | 0 | 0 | 0 | 128 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 1 | 1 | 0 | 24,602 | 6,565 | 6,088 | 11,726 |
| Group/Directors Accounts | 865 | 0 | 0 | 0 | 0 | 0 | 0 | 1,070 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 15,238 | 17,811 | 1,205 | 17,714 | 0 | 0 | 0 | 0 |
| total current liabilities | 16,103 | 17,812 | 1,206 | 17,842 | 24,602 | 6,565 | 6,088 | 12,796 |
| loans | 28,876 | 39,784 | 50,000 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 28,876 | 39,784 | 50,000 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 44,979 | 57,596 | 51,206 | 17,842 | 24,602 | 6,565 | 6,088 | 12,796 |
| net assets | 107,371 | 82,886 | 54,646 | 108,055 | 65,283 | 12,594 | 112 | 1 |
| total shareholders funds | 107,371 | 82,886 | 54,646 | 108,055 | 65,283 | 12,594 | 112 | 1 |
| Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | ||||||||
| Depreciation | 19,351 | 18,387 | 9,592 | 0 | 0 | 0 | ||
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Tax | ||||||||
| Stock | 0 | 0 | 0 | -54,467 | 54,467 | 0 | 0 | 0 |
| Debtors | 19,000 | 10,000 | 10,000 | 7,000 | -17,589 | 11,389 | -5,921 | 12,121 |
| Creditors | -1 | 0 | 1 | -24,602 | 18,037 | 477 | -5,638 | 11,726 |
| Accruals and Deferred Income | -2,573 | 16,606 | -16,509 | 17,714 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||||
| Investing Activities | ||||||||
| capital expenditure | ||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||
| Financing Activities | ||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 865 | 0 | 0 | 0 | 0 | 0 | -1,070 | 1,070 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | -10,908 | -10,216 | 50,000 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||
| interest | ||||||||
| cash flow from financing | ||||||||
| cash and cash equivalents | ||||||||
| cash | -10,978 | -10,551 | -23,652 | 74,132 | 0 | 0 | -676 | 676 |
| overdraft | 0 | 0 | -128 | 128 | 0 | 0 | 0 | 0 |
| change in cash | -10,978 | -10,551 | -23,524 | 74,004 | 0 | 0 | -676 | 676 |
entcancercare ltd Credit Report and Business Information
Entcancercare Ltd Competitor Analysis
Perform a competitor analysis for entcancercare ltd by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other micro companies, companies in MK5 area or any other competitors across 12 key performance metrics.
entcancercare ltd Ownership
ENTCANCERCARE LTD group structure
Entcancercare Ltd has no subsidiary companies.
Ultimate parent company
ENTCANCERCARE LTD
09558725
entcancercare ltd directors
Entcancercare Ltd currently has 3 directors. The longest serving directors include Mr Mrinal Supriya (Apr 2015) and Mrs Nidhi Supriya (Feb 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Mrinal Supriya | England | 46 years | Apr 2015 | - | Director |
| Mrs Nidhi Supriya | United Kingdom | 44 years | Feb 2017 | - | Director |
| Mr Rajiv Bhasin | England | 53 years | Feb 2022 | - | Director |
P&L
April 2023turnover
248.9k
+156%
operating profit
34.7k
0%
gross margin
42.9%
-3.1%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
April 2023net assets
107.4k
+0.3%
total assets
152.4k
+0.08%
cash
29k
-0.27%
net assets
Total assets minus all liabilities
Similar Companies
entcancercare ltd company details
company number
09558725
Type
Private limited with Share Capital
industry
86210 - General medical practice activities
incorporation date
April 2015
age
9
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
April 2023
previous names
N/A
accountant
-
auditor
-
address
2 livesey hill, shenley lodge, milton keynes, buckinghamshire, MK5 7EG
Bank
-
Legal Advisor
-
entcancercare ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to entcancercare ltd.
entcancercare ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ENTCANCERCARE LTD. This can take several minutes, an email will notify you when this has completed.
entcancercare ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
